Sara Coca Membribes, Clinical Research Fellow at Barts Health NHS Trust, shared a post on X about a recent article she and her colleagues co-authored, adding:
“Just out in Nature Reviews Clinical Oncology
”Biomarkers in UC’. HER2, FGFR3, PD-L1 are approved and ctDNA is becoming a reality. We address methodological inconsistencies, need for standardization and AI integration.
FGFR3 = the only established predictive biomarker but increased variability in detection methods (DNA/RNA, PCR, ctDNA).
Promising randomised ph3 in 1L (FORAGER-2) and NMIBC (MoonRISe-1).
PD-L1 has been assessed using TC, IC, CPS with inconsistent results across scoring, cut-off and assays.
No prospective trial has shown predictive value which is reflected in differing approvals (FDA vs EMA).
ctDNA is currently the most promising biomarker in UC.
- Strong prognostic value
- Correlation with MRD after curative therapy
- Predictive role? Bladder-sparing? →
Ongoing trials (Table).
Biomarkers for ADCs in UC are still evolving.
Clarity is needed in HER2 to avoid the challenges seen with PD-L1.
T-DXd approved in HER2 3+ (but n=16) and recent data support DV+Toripalimab in HER2 1-3+.
Work on nectin-4, TROP-2 and HER3 is ongoing.”
Title: Towards biomarker-driven therapies for urothelial carcinoma
Authors: Sara Coca Membribes, Bernadett Szabados, Thomas Powles
Read the Full Article on Nature Reviews Clinical Oncology
More posts featuring Sara Coca Membribes.
